Spartan Bioscience Announces Strategic Investment from Canon U.S.A.
News Mar 18, 2015
Spartan Bioscience Inc. has received a strategic investment from Canon U.S.A., Inc., a leader in digital imaging solutions. As part of the investment, Seymour Liebman will be joining Spartan’s Board of Directors. Mr. Liebman is executive vice president, chief administrative officer and general counsel of Canon U.S.A., Inc., senior executive officer of Canon Inc., vice chairman of Canon Solutions America, Inc. and is a member of the Board of Directors of Canon BioMedical, Inc., a recently established wholly-owned subsidiary of Canon U.S.A., Inc.
In addition to the strategic investment, Canon BioMedical and Spartan Bioscience plan to explore areas to work together on the development of future diagnostic products.
“We are delighted to welcome Canon U.S.A. as a strategic investor in Spartan Bioscience,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Spartan is forging new markets for rapid genetic testing, and we are excited to accelerate our progress with this investment.”
“Canon is excited to make this investment in Spartan Bioscience and I am also honored to join the Board of Directors,” said Liebman. “With the recent establishment of Canon BioMedical, it is a natural fit for us to explore areas with Spartan to uncover new diagnostic testing methods that can help benefit the health of future generations.”
Attacking Telomeres Offers First Effective Glioblastoma TherapyNews
Blocking TRF1 – a telomere protector – interrupts tumour growth and increases survival in various mouse models of glioblastoma.READ MORE
“Tracking” Nanoagents Can Illuminate Very Small Diseased TissuesNews
Polymer nanoagents that can ‘light up’ tiny areas of diseased tissues that conventional methods fail to detect, have been created by a research team led by Nanyang Technological University, Singapore.READ MORE